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Abstract The effects of the novel vasoactive regulatory peptide, 
adrenomedullin, on human oral keratinocytes was investigated. 
Adrenomedullin, acting via its specific receptor, stimulated a 
dose-dependent increase in DNA synthesis, and, in addition, 
stimulated further changes in the cell cycle resulting in the 
proliferation of keratinocytes. When cells were incubated in the 
presence of increasing concentrations of adrenomedullin, there 
was a rapid and dose-dependent rise in intracellular cyclic AMP 
levels. Stimulation of mitogenesis and cell proliferation in these 
cells were mimicked by the cell permeable cAMP analogue, di-
butyryl cAMP. Adrenomedullin-stimulated mitogenesis was 
attenuated by the adenylyl cyclase inhibitor SQ22,536, but was 
unaffected by inhibitors of PKC, tyrosine kinase or the CGRP 
receptor antagonist, CGRP(8-37). These data identify adreno-
medullin as a new mitogenic regulatory peptide of keratinocytes 
acting via the cAMP cascade. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Adrenomedullin (AM) is a newly discovered member of the 
calcitonin peptide family and is a vasoactive 52 amino acid 
peptide [1]. AM mRNA and protein are widely distributed in 
human and rat tissues, including the heart, aorta, lung and 
adrenal gland, and it is detectable in the plasma [2-5]. Binding 
sites for AM have been identified in many human tissues such 
as the adrenal glands, lung, heart, kidney and in primary 
cultures of aortic endothelial cells and vascular smooth muscle 
cells (VSMC) [3-6]. These findings have identified AM as a 
novel component of the homeostatic regulatory peptide sys-
tem, but the cellular responses and the signalling pathways 
that are mediated by this peptide are not fully elucidated. 
Previous studies have shown that AM stimulates increases 
in intracellular cAMP levels in VSMC and rat adrenocortical 
cells [6]. It has also been shown to elevate intracellular Ca2+ in 
bovine aortic endothelial cells via a G-protein which is chol-
era-toxin sensitive [6]. Studies with AM, however, have been 
complicated by the knowledge that some of the effects can be 
blocked by the calcitonin gene-related peptide (CGRP) recep-
tor antagonist CGRP(8-37) [1]. It has been shown that the 
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AM can bind to the CGRP receptor and CGRP(8-37) can 
bind to AM receptor, albeit weakly [8], suggesting that the 
effects induced by AM may be mediated via CGRP receptors. 
We have demonstrated, previously, that the cloned rat AM 
receptor binds AM specifically and this binding is not dis-
placed by CGRP [7]. In order to study and characterise fur-
ther the cellular effects of AM, a cell line is required which has 
specific AM and CGRP receptors. 
This study reports that H357 oral keratinocytes express 
receptors of specific high affinity for AM, but not CGRP, 
and that AM causes increases in cAMP accumulation, induces 
mitogenesis and stimulates cell proliferation. Furthermore, 
these effects are mimicked by the cell permeable cAMP ana-
logue, di-butyryl cAMP. AM-stimulated mitogenesis of H357 
cells is abolished in the presence of SQ22,536, a specific an-
tagonist of adenylyl cyclase. Inhibitors of PKC (Ro31-8220), 
tyrosine kinase (lavendustin A) or the CGRP receptor antag-
onist, CGRP(8-37) have no effect on AM-stimulated mitogen-
ic events. Our results identify AM as a new peptide growth 
factor acting via its own specific receptor and the cAMP cas-
cade. 
2. Materials and methods 
2.1. Materials 
Human AM, CGRP(8-37), CGRP I, II, amylin and [,25I]AM were 
obtained from Phoenix Pharmaceuticals Inc., San Francisco, CA, 
USA. Tissue culture materials were from Life Technologies Ltd., Pais-
ley, UK. [3H]cAMP was from Amersham International Ltd., Amer-
sham, UK. SQ22,536 and lavendustin A were obtained from Semat 
Technical (UK) Ltd., Herts, UK. All other reagents were the best 
grade available. 
2.2. Cell culture 
H357 cells were maintained in keratinocyte growth medium (KGM) 
supplemented with 10% fetal bovine serum and antibiotics in a hu-
midified atmosphere containing 5% CO2 and 95% air at 37°C [9]. 
Thymidine incorporation assays were carried out using confluent, 
quiescent cultures of H357 cells, in 6-well plates, that were incubated 
in KGM containing 1 uCi/ml [3H]thymidine and increasing concen-
trations of AM in the presence of 50 uM of IBMX. In other experi-
ments cells were incubated in the presence of 10 nmol/1 AM and 
SQ22,536 (10 mol/1), Ro31-8220 (150 nmol/1), lavendustin A (500 
nmol/1) or CGRP(8-37) (1 nmol/1). After 24 h, DNA synthesis was 
assessed by measuring the [3H]thymidine incorporated into acid-pre-
cipitable material [10]. 
In other experiments, semi-confluent quiescent cultures of H357, in 
96-well plates, were incubated in KGM in the absence or presence of 
various concentrations of AM ± inhibitors and 50 uM IBMX. After 
24 h, cell proliferation was measured by adding 20 ul of MTS tetra-
zolium [11,12] and incubating the plates for up to 4 h in a humidified 
atmosphere. MTS tetrazolium is reduced by proliferating cells into a 
coloured formazan product that is soluble in tissue culture medium. 
Absorbance was recorded at 490 nm with a 96-well plate reader. 
2.3. Receptor-binding assays 
The binding assay used was a modified form of a previously de-
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scribed method [8]. Confluent H357 cells were incubated at room 
temperature for 60 min with 0.1 nmol/1 [125I]AM and increasing con-
centrations of unlabelled AM, CGRP I, CGRP II, CGRP(8-37) or 
amylin, in binding buffer (20 mmol/1 HEPES, pH 7.4, 5 mmol/1 
MgCl2, 10 mmol/1 NaCl, 4 mmol/1 KC1, 1 mmol/1 EDTA). Cells 
were solubilised in 0.1 mol/1 NaOH and tracer bound to the cells 
was determined by y spectroscopy. 
2.4. cAMP measurements 
H357 cells were washed twice with PBS and incubated in KGM 
with various factors as indicated for 20 min in the presence of 50 uM 
IBMX. Medium was then removed and cAMP was measured in an 
aliquot using an in-house specific binding protein assay [13]. Results 
shown are derived from four separate experiments carried out in trip-
licate. 
2.5. Statistical analysis 
Arithmetic means and standard deviations were calculated. One-
way analysis of variance was used to test whether factors had an effect 
on basal (control) levels of cAMP, cell proliferation and mitogenesis, 
and Student's r-test was used to determine the effect of inhibitors on 
AM-stimulated events using the Minitab statistics software package. 
Binding parameters were determined using the LIGAND program 
[14]. 
3. Results and discussion 
The binding characteristics of AM receptors were studied in 
the H357 human oral cell line. Binding of [125I]AM was shown 
to be saturable for the receptor (Fig. 1A) and analysis of the 
data, by the curve fitting program LIGAND, and Hill analysis 
predicted the probability of a single site model vs a two-site 
model (P<0.05; Hill coefficient 0.891). Scatchard analysis 
revealed the presence of a single population of binding sites 
(Fig. IB) and the calculated Kz, of the receptor was 8.25 nmol/ 
1 with a 5 m a x of 466 fmol/mg protein. Fig. 1C shows the 
displacement of [125I]AM by unlabelled AM, CGRP I, 
CGRP II, CGRP(8-37) or amylin on intact H357 cells. Dis-
placement of [125I]AM binding by unlabelled peptide showed 
that AM tracer was displaced in a dose-dependent manner 
and up to 90% was displaced by 50 nmol/1 AM. Fig. 1C shows 
that CGRP I, CGRP II, CGRP(8-37) or amylin did not sig-
nificantly displace [125I]AM binding in parallel cultures of 
H357 cells, even at concentrations up to 10~6 mol/1. These 
data demonstrate that H357 cells express specific receptors 
for AM. 
There was a significant increase of intracellular cAMP pro-
duction by H357 cells in response to AM (Fig. 2) with thresh-
old stimulation occurring around 10 pmol/1, peak response at 
10 nmol/1 and an EC50 of 1 nmol/1. Although it has been 
reported that AM can stimulate increases in both cAMP levels 
and intracellular calcium mobilisation [7], studies have shown 
that AM-stimulated cAMP actions can be attenuated by chol-
era toxin pretreatment, suggesting its effects can partly be 
mediated via cytosolic calcium [7]. No mobilisation of calcium 
was seen in the H357 cells in response to AM (data not 
shown). Coupling of the receptor to adenylyl cyclase was fur-
ther assessed by exposing cells to 10 nmol/1 SQ22,536, a po-
tent and specific inhibitor of adenylyl cyclase, in the absence 
or presence of 10 nmol/1 AM. Fig. 2 (inset) shows that the 
cAMP response to AM was significantly (P< 0.001) attenu-
ated in the presence of SQ22,536. Inhibitors of PKC or tyro-
sine kinase activity (10 nmol/1 of either Ro31-8220 or laven-
dustin A, respectively) had no effect on cAMP levels in 
response to AM (Fig. 2, inset). The CGRP receptor antago-
nist, CGRP(8-37), was without effect on AM-stimulated 
cAMP levels. These data suggest that AM does not activate 
either PKC or tyrosine kinase and the stimulatory effect of 
AM on cAMP levels appears to be mediated via specific AM 
receptors coupled to adenylyl cyclase. 
Previous studies using AM and CGRP(8-37) have demon-
strated that some of the effects of AM are mediated via 
CGRP receptors. These include AM-stimulated rises in 
cAMP levels in neuroblastoma cells [15] and AM-mediated 
vasodilation in the microvasculature of the hamster cheek 
pouch and rat skin [16]. However, it has also been reported 
that some effects of AM are mediated by AM receptors and 
not via CGRP receptors. These include AM-stimulated cAMP 
production in HUVECs [17] and vasodepressor responses to 
AM in the hindquarter vascular bed of the rat [18]. The data 
presented in this study (Fig. 2) indicate that in human oral 
keratinocytes AM acts via cAMP by binding to its own spe-
cific receptor. 
When H357 cells, labelled with [3H]thymidine, were incu-
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Fig. 1. Saturation curve, Scatchard analysis and displacement curves of human [125I]AM binding. A: Concentration dependence of [125I]AM 
binding to intact H357 cells showing specific (circles) and non-specific (squares) binding. B: Scatchard analysis of specific [125I]AM binding. C: 
Displacement of [125I]AM binding by increasing concentrations of AM, CGRP I, CGRP II, CGRP(8-37) or amylin. Each point represents the 
mean of triplicate determinations. 
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bated in the presence of AM there was a concentration-de-
pendent increase in [3H]thymidine incorporation as shown in 
Fig. 3. Maximum incorporation was observed at 10 nmol/1 
AM. Since it was clear that AM mediated its effects via 
cAMP it was decided to investigate whether the mitogenic 
effects of AM were also cAMP related. AM-stimulated 
H357 cells, labelled with [3H]thymidine, were incubated in 
the presence of various enzyme inhibitors. Fig. 3 (inset) shows 
that SQ22,536 had profound inhibitory effects on 
[3H]thymidine uptake whereas Ro31-8220 or lavendustin A 
had no effect. These results strongly suggest that AM-induced 
DNA synthesis in H357 cells is not mediated via PKC or 
tyrosine kinase. Furthermore, addition of the CGRP receptor 
antagonist CGRP(8-37) to the [3H]thymidine-labelled cells 
did not affect DNA synthesis in response to 10 nmol/1 AM, 
lending additional support that the effects of AM are medi-
ated by specific AM receptors and not by CGRP receptors. 
Cell proliferation studies, using an MTS tetrazolium-based 
colorimetric assay, demonstrated that AM caused significant 
increases in cell proliferation with maximum incorporation 
occurring at 1 nmol/1 AM (2.59 X105 ±0.18 cells vs 
1.02xl05±1.09 untreated cells; P<0.001 compared to con-
trol). When cells were incubated with SQ22,536, cellular pro-
liferation was significantly attenuated in response to 1 nmol/1 
AM (1.15 X105 ± 0.08 cells vs 2.59 X 105 ± 0.18 untreated cells; 
P< 0.001 compared to AM alone). Furthermore, the cell-per-
meable cAMP analogue, dbcAMP, also caused a significant 
increase in cell growth (2.22 X105 ±0.19 cells vs 
1.02 X105± 0.09 untreated cells; P< 0.001 compared to con-
trol), suggesting that this effect on proliferation is mediated 
via cAMP or a cAMP-mediated mechanism. However, the 
PKC inhibitor, Ro31-8220, the tyrosine kinase inhibitor, lav-
endustin A, and CGRP(8-37) had no effect on cell prolifer-
ation in response to 1 nmol/1 AM at any concentration used 
(data not shown). 
Increases in levels of cAMP have been identified as a mito-
genic signal for many cells and AM has been shown to stim-
ulate cAMP production in a wide variety of cells. These in-
clude Schwann cells [19,20], breast tumour cells [21], thyroid 
epithelial cells [22] and AML193, a leukaemic cell line [23]. It 
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Fig. 2. Dose-dependent increases in cAMP production in H357 cells 
in response to AM. Inset: Bar graph showing the effects of various 
inhibitors on 10 nmol/1 AM-stimulated cAMP levels. SQ, SQ22,536 
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Fig. 3. Dose-dependent increases in [3H]thymidine uptake in intact 
H357 cells in response to AM. Inset: Bar graph showing the effects 
of various agents on 10 nmol/1 AM-stimulated cAMP levels. SQ, 
SQ22,537 (10 nmol/1); Ro, Ro31-8220 (150 nmol/1); LA, lavendustin 
A (500 nmol/1); CG, CGRP(8-37) (1 umol/1). Values are 
means ±S.E.M., n = 4. *P<0.05, ***P< 0.001 compared with basal 
levels of DNA synthesis (analysis of variance). + + + P < 0.001 com-
pared with AM alone (Student's Mest). 
is clear that AM acts in a similar manner on cultured oral 
keratinocytes. Previous studies have shown that regulatory 
peptides have a role in controlling cell proliferation, in addi-
tion to the growing list of neuropeptides and growth factors 
that are known to promote cell proliferation [24-27]. 
Many peptides with mitogenic properties, such as endothe-
lin, angiotensin II and vasopressin, mediate their cellular ef-
fects via activation of phospholipase C and, thus, production 
of inositol phosphates and diacylglycerol, as well as PKC 
activation [25-27]. Experiments conducted in this study sug-
gest that PKC is not activated by AM in H357 cells. Addi-
tionally, in experiments where cells were labelled with 
[3H]inositol, AM did not induce the production of inositol 
trisphosphate, suggesting AM does not activate phospholipase 
C (data not shown). In contrast, our findings indicate that 
AM is a novel mitogenic peptide for human oral keratinocytes 
and that these mitogenic effects are mediated via cAMP, a 
signal that is known to cause increased/enhanced cell prolif-
eration in a number of cell types. These results lend further 
support for the role of peptides, including AM, in the control 
and regulation of cell proliferation. 
Acknowledgements: The authors wish to thank the British Heart 
Foundation, The Royal Society and Medical Research Council for 
support. D.W.B. is the recipient of an MRC studentship. The authors 
also wish to thank Professor S.S. Prime, University of Bristol and Dr 
D. Bradshaw, Roche Products Ltd. for the generous gifts of H357 
cells and Ro31-8220 respectively, used in these studies. 
References 
[1] Nuki, C, Kawasaki, H., Kitamura, K., Takenaga, M., Kangawa, 
K., Eto, T. and Wada, A. (1993) Biochem. Biophys. Res. Com-
mun. 196, 245-251. 
[2] Kitamura, K., Sakata, J., Kangawa, K., Kojima, M., Matsuo, H. 
and Eto, T. (1993) Biochem. Biophys. Res. Commun. 194, 720-
725. 
[3] Sakata, J., Shimokubo, T., Kitamura, K., Nakamura, S., Kanga-
wa, K., Matsuo, H. and Eto, T. (1993) Biochem. Biophys. Res. 
Commun. 195, 921-927. 
[4] Ichiki, Y., Kitamura, K., Kangawa, K., Kawamoto, M., Matsuo, 
H. and Eto, T. (1994) FEBS Lett. 338, 6-10. 
[5] Sakata, J., Shimokubo, T., Kitamura, K., Nishizono, M., Iehiki, 
290 S. Kapas et al.lFEBS Letters 418 (1997) 287-290 
Y., Kangawa, K., Matsuo, H. and Eto, T. (1994) FEBS Lett. 
352, 105-108. 
[6] Sugo, S., Minamino, N., Kangawa, K., Miyamoto, K., Kita-
mura, K., Sakata, J., Eto, T. and Matsuo, T. (1994) Biochem. 
Biophys. Res. Commun. 201, 1160-1166. 
[7] Kapas, S., Catt, K.J. and Clark, A.J.L. (1995) J. Biol. Chem. 270, 
25344-25347. 
[8] Sugiyama, M., Speight, P.M., Prime, S.S. and Watt, F.M. (1993) 
Carcinogenesis 14, 2171-2176. 
[9] Hatakeyama, H., Miyamori, I., Fujita, T., Takeda, Y., Takeda, 
R. and Yamamoto, H. (1994) J. Biol. Chem. 2769, 24316-24320. 
[10] Cory, A.H., Owen, T.C., Barltrop, J.A. and Cory, J.G. (1991) 
Cancer Commun. 3, 207-212. 
[11] Cory, A.H., Owen, T.C., Barltrop, J.A. and Cory, A.G. (1991) 
Cancer Communications 3, 207-212. 
[12] Riss, T.L. and Morevec, R.A. (1992) Mol. Biol. Cell. 3, 184a. 
[13] Kapas, S., Orford, CD. , Barker, S., Hinson, J.P. and Vinson, 
G.P. (1992) J. Mol. Endocrinol. 9, 47-54. 
[14] Munson, P.J. and Rodbard, D. (1980) Anal. Biochem. 107, 220-
239. 
[15] Zimmerman, U., Fischer, J.A. and MufT, R. (1995) Peptides 16, 
421^124. 
[16] Hall, J.M., Siney, L., Lippton, H., Hyman, A., Jaw, K.C. and 
Brain, S.D. (1995) Br. J. Pharmacol. 114, 592-597. 
[17] Kato, J., Kitamura, K., Kangawa, K. and Eto, T. (1995) Eur. J. 
Pharmacol. 289, 383-385. 
[18] Feng, C.J., Kang, B., Kaye, A.D., Kadowitz, P.J. and Nossaman, 
B.D. (1994) Life Sci. 55, PL433-PL438. 
[19] Cheng, L., Khan, M. and Mudge, A.W. (1995) J. Cell. Biol. 129, 
789-796. 
[20] Tzeng, S.F., Deibler, G.E., Neuberger, T.J. and Devries, G.H. 
(1995) J. Neurosci. Res. 42, 758-767. 
[21] Strobl, J.S., Wonderlin, W.F. and Flynn, D.C. (1995) Gen. Phar-
macol. 26, 1643-1649. 
[22] Pirson, J., Coulonval, K.C, Lamy, F. and Dumont, J.E. (1996) 
J. Cell. Physiol. 158, 59-70. 
[23] Barge, R.M.Y., Falkenberg, J.H.F., Willemze, R. and Maassen, 
J.A. (1997) Biochim. Biophys. Acta 1355, 141-146. 
[24] Withers, D.J., Coppock, H.A., Seufferlein, T., Smith, D.M., 
Bloom, S.R. and Rozengurt, E. (1996) FEBS Lett. 378, 83-87. 
[25] Rozengurt, E. (1992) Curr. Opin. Cell. Biol. 4, 161-164. 
[26] Dietrich, J.B. (1994) Cell. Mol. Biol. 40, 731-746. 
[27] Taipale, J. and Keskioja, J. (1997) FASEB J. 11, 51-59. 
